Meget almindelige negative reaktioner, som er iagttaget under de tre mest relevante kliniske forsøg med LITAK hos 279 patienter, som blev behandlet for forskellige indikationer, og hos 62 patienter med hårcelleleukæmi (HCL) var myelosuppression, specielt alvorlig neutropeni (41% (113/ 279), 98% (HCL, 61/ 62)), alvorlig trombocytopeni (21% (58/ 279), 50% (HCL, 31/ 62)) og alvorlig anæmi (14% (21/ 150), 55% (HCL, 34/ 62)), såvel som alvorlig immunsuppression/ lymfopeni (63% (176/ 279), 95% (HCL, 59/ 62)), infektioner (39% (110/ 279), 58% (HCL, 36/ 62)) og feber (op til 64%).
Very common adverse reactions observed during the three most relevant clinical trials with LITAK in 279 patients treated for various indications and in 62 patients with hairy cell leukaemia (HCL) were myelosuppression, especially severe neutropenia (41% (113/ 279), 98% (HCL, 61/ 62)), severe thrombocytopenia (21% (58/ 279), 50% (HCL, 31/ 62)) and severe anaemia (14% (21/ 150), 55% (HCL, 34/ 62)), as well as severe immunosuppression/ lymphopenia (63% (176/ 279), 95% (HCL, 59/ 62)), infections (39% (110/ 279), 58% (HCL, 36/ 62)) and fever (up to 64%).